Written Question · S2W-20285 · Session 2
Whether NHS Quality Improvement Scotland has made any recommendations for any particular drugs not to be used for the treatment of Alzheime…
The question
To ask the Scottish Executive whether NHS Quality Improvement Scotland has made any recommendations for any particular drugs not to be used for the treatment of Alzheimer’s Disease on the NHS.
The answer
The Medicines and Healthcare products Regulatory Agency (MHRA) provides a licence for any given medicine in the UK. This ensures that medicines meet acceptable standards on safety, quality and efficacy. The Scottish Medicines Consortium (SMC) advises NHSScotland on the costs and benefits of new medicines after they have been licensed by the Medicines and Healthcare products Regulatory Agency/European Medicines Evaluation Agency.
Currently the Scottish Medicines Consortium does not recommend that Memantine (Ebixa ®) is used to treat moderately severe to severe Alzheimer’s Disease.
In England, the National Institute for Clinical Excellence (NICE) has published an appraisal consultation document entitled “Alzheimer’s disease
- donepezil, rivastigmine, galantamine and memantine”. The consultation closed on 22 March 2005 and can be accessed at http://www.nice.org.uk/page.aspx?o=245912. The consultation document does not constitute the Institute’s formal guidance on these drugs and the recommendation made is preliminary and may change after the consultation.
Once the final recommendation has been made NHS Quality Improvement Scotland will consider the implications of the guidance from NICE on these drugs for NHSScotland.
Currently the Scottish Medicines Consortium does not recommend that Memantine (Ebixa ®) is used to treat moderately severe to severe Alzheimer’s Disease.
In England, the National Institute for Clinical Excellence (NICE) has published an appraisal consultation document entitled “Alzheimer’s disease
- donepezil, rivastigmine, galantamine and memantine”. The consultation closed on 22 March 2005 and can be accessed at http://www.nice.org.uk/page.aspx?o=245912. The consultation document does not constitute the Institute’s formal guidance on these drugs and the recommendation made is preliminary and may change after the consultation.
Once the final recommendation has been made NHS Quality Improvement Scotland will consider the implications of the guidance from NICE on these drugs for NHSScotland.
In the Official Report
No contribution in the Official Report cites S2W-20285 by reference.